Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 28, 2025
Modern Heart and Vascular Institute Opens New Clinic in Spring, Texas
EIN Presswire
·
April 28, 2025
Modern Heart and Vascular Institute, Cardiology Practice, Opens New Clinic in Spring, Texas SPRING, TX, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- Modern Heart and Vascular Institute has announced the opening of its newest clinic in Spring, …
Trucent Renewable Chemicals Secures TruFA® Trademark
EIN Presswire
·
April 28, 2025
TruFA® is now a registered trademark—offering a certified, spec-ready alternative to TOFA that’s domestically sourced and U.S. produced. VAN WERT, OH, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- Trucent Renewable Chemicals Secures TruFA® …
U.S. Amputee Soccer Names 2026 World Cup Qualifiers Roster, Launches Fundraiser for Mexico
EIN Presswire
·
April 28, 2025
STONY BROOK, NY, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- The American Amputee Soccer Association is proud to announce the official roster of players who will represent the United States in the 2026 Amputee Soccer World Cup Qualifiers, to be …
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a …
UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine
GlobeNewswire
·
April 28, 2025
LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by …
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
GlobeNewswire
·
April 28, 2025
MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET1 imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide …
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
– Oral and poster presentations will highlight advancements from ElevateBio’s two business units: Life Edit, its gene editing and R…
ARCPOINT REPORTS 2024 YEAR END FINANCIAL RESULTS AND ANNOUNCES MANAGEMENT CHANGE
GlobeNewswire
·
April 28, 2025
Greenville, South Carolina, April 28, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to report that it has filed its 2024 year end, audited Financial Statements and related Management Discussion and Analysis as …
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
GlobeNewswire
·
April 28, 2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
GlobeNewswire
·
April 28, 2025
Reflects business philosophy of commercial success through patient accessibility Recently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder …
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability …
Arbor Biotechnologies to Present Foundational Data for PH1 and CNS Programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
- Oral presentation to include preclinical data supporting the clinical advancement of ABO-101 for the treatment of primary hyperoxaluria type 1 - Four poster presentations collectively demonstrate advancement of company’s differentiated CNS gene editing …
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual …
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate …
Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson’s disease and adrenomyeloneuropathy in oral and poster presentations at the American …
Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT
GlobeNewswire
·
April 28, 2025
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, today announced that Co-Founder and Chief Scientific Officer, Dr. Victor Hernandez, …
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations, at the upcoming 28th Annual Meeting of the American Society of Gene …
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewswire
·
April 28, 2025
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today …
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …